

## SuperSonic Imagine appoints Jérôme Destoppeleir as Chief Financial Officer

March 23, 2015 – SuperSonic Imagine (Euronext: SSI, FR0010526814, eligible PEA-PME), a company specializing in ultrasound medical imaging and pioneer of ShearWave™ Elastography and UltraFast™ Doppler, announced today the appointment of Jérôme Destoppeleir as the Company's new Chief Financial Officer. He is replacing Gordon Waldron, who is leaving on April 15, 2015 after more than 4 years in this post.

Jérôme Destoppeleir, aged 46, will direct the Financial strategy of the Group through its next phase of international growth and development. A graduate of HEC Paris, he began his career in 1992 within the PERNOD RICARD group, joining the ONET group in 2000 where he spent 9 years as CFO. He then held a number of CFO positions at the DELTA PLUS group, PGA MOTORS and HOMAIR VACANCES.

Jacques Souquet, SuperSonic Imagine's Founder and Chief Executive Officer, says: *"I would like to welcome Jérôme, who has demonstrated first-rate professional abilities throughout his career, essential qualities to successfully undertake his new mission with SuperSonic Imagine. On behalf of the Board and management team, I would also like to wholeheartedly thank Gordon for his remarkable contribution, his unwavering commitment and for all that he has accomplished within our Company. He has played a formative role in the Company's development by brilliantly negotiating two major fund-raising rounds and successfully leading last year's IPO on the Euronext stock exchange. Gordon's decision is in no way motivated by any professional considerations within the Company and I wish him all the best in his future endeavors."*

Gordon Waldron adds: *"I also want to warmly welcome Jerome to the Company. I leave with great memories of the years spent working with the employees and shareholders of SuperSonic Imagine. We have accomplished a lot together and brought the Company into a new league. This transition was initiated for purely personal reasons and I wanted to make sure that it happened at the most suitable time for SuperSonic Imagine. Right now the Company is financially solid and in the good hands of a highly experienced management team, which is fully equipped to implement a high-growth strategy."*

Next press release: Q1 2015 revenue, on April 21, 2015.

### À propos de SuperSonic Imagine

Fondée en 2005 et basée à Aix-en-Provence (France), SuperSonic Imagine est une entreprise spécialisée dans le secteur de l'imagerie médicale. La société conçoit, développe et commercialise une plateforme échographique révolutionnaire, Aixplorer®, qui exploite une technologie UltraFast™ à une cadence d'acquisition environ 200 fois plus rapide que les systèmes concurrents. Aixplorer® est le seul échographe à pouvoir imager deux types d'ondes : les ondes ultrasonores permettant de construire des images d'une qualité exceptionnelle; les ondes de cisaillement permettant aux médecins de visualiser et analyser en temps réel la dureté des tissus, grâce à une procédure fiable, reproductible, et non invasive. Cette innovation, l'Élastographie ShearWave™, améliore la détection et la caractérisation de multiples pathologies dans de nombreuses applications, notamment le sein, la thyroïde, le foie ou la prostate. SuperSonic Imagine dispose des autorisations réglementaires nécessaires pour une commercialisation d'Aixplorer® sur les principaux marchés. Au cours des dernières années, SuperSonic Imagine a bénéficié du soutien de plusieurs investisseurs de premier plan, parmi lesquels Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital, NBGI. Pour plus d'information sur SuperSonic Imagine, visitez [www.supersonicimagine.fr](http://www.supersonicimagine.fr)

**SuperSonic Imagine**  
Marketing & Communication  
Emmanuelle Vella  
[emmanuelle.vella@supersonicimagine.com](mailto:emmanuelle.vella@supersonicimagine.com)  
04 86 79 03 27

**NewCap**  
Investor Relations - EU  
Pierre Laurent / Florent Alba  
[supersonicimagine@newcap.fr](mailto:supersonicimagine@newcap.fr)  
+33 1 44 71 98 55

**Blueprint Life Science Group**

Investor Relations - US  
Candice Knoll  
[cknoll@bplifescience.com](mailto:cknoll@bplifescience.com)  
415 375 3340 Ext. 105



**ComCorp**

Media Relations  
Florence Portejoie  
[fportejoie@comcorp.fr](mailto:fportejoie@comcorp.fr)  
+33 1 58 18 32 58 - +33 6 88 84 81 74  
Adelaïde Manester  
[amanester@comcorp.fr](mailto:amanester@comcorp.fr)  
+33 1 58 18 32 58 - +33 6 70 45 74 37